2025-05-30 - Analysis Report
Okay, here's an analysis report for Transmedics Group Inc (TMDX) based on the data you provided, formatted for clarity and with a focus on key insights.

**Report on Transmedics Group Inc (TMDX)**

**Company Overview:** Transmedics Group Inc. is a medical technology company focused on preserving organ viability for transplant.

**1. Performance vs. S&P 500 (VOO)**

*   **TMDX Cumulative Return:** 247.38%
*   **VOO Cumulative Return:** 52.03%
*   **Absolute Deviation:** 195.4
*   **Relative Deviation:** 72.8 (Indicates TMDX's performance is in the higher range compared to its historical deviation from VOO)

**Analysis:** TMDX has significantly outperformed the S&P 500 (VOO). The high relative deviation suggests that this outperformance, while substantial, is within the historical range of its divergence from the index.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD   | Alpha   | Beta  | Cap(B) |
|------------|---------|-------|---------|-------|--------|
| 2019-2021  | -4.0%   | 63.4% | -56.0%  | -0.0  | 0.7    |
| 2020-2022  | 140.0%  | 68.3% | 134.0%  | 0.0   | 2.1    |
| 2021-2023  | 95.0%   | 69.4% | 80.0%   | 0.3   | 2.7    |
| 2022-2024  | 147.0%  | 82.8% | 131.0%  | 0.3   | 2.1    |
| 2023-2025  | 128.0%  | 82.8% | 99.0%   | 0.5   | 4.3    |

*   **CAGR:** The Compound Annual Growth Rate is quite high.
*   **MDD:** The Maximum Drawdown is also quite high.
*   **Alpha:** Positive Alpha indicates the stock's ability to generate excess returns relative to the benchmark index.
*   **Beta:** A Beta around 0 suggests low correlation with the market.
*   **Cap:** A recent large cap increase suggests substantial business growth

**Analysis:** The alpha indicates the TMDX has consistently generated returns beyond what would be expected based on market movements alone. The low Beta values indicate that TMDX's price movements are not strongly correlated with the broader market.

**2. Recent Price Action**

*   **Current Price:** 127.69
*   **Last Market Data:** {'price': 127.69, 'previousClose': 128.62, 'change': -0.72}
*   **5-Day Moving Average:** 126.486
*   **20-Day Moving Average:** 113.6835
*   **60-Day Moving Average:** 88.3647

**Analysis:** The price is above all three moving averages, indicating an upward trend. The 5-day moving average is close to the current price.

**3. Market Risk Indicators**

*   **Market Risk Indicator (MRI):** 0.366 (Low Risk)
*   **RSI:** 88.57 (Overbought)
*   **PPO:** -0.3703
*   **Hybrid Signal:** Sell 70% of holdings (Caution - MRI: 0.37)
*   **Recent Relative Deviation Change (20-day):** 3.9 (+) - Short-term increase
*   **Expected Return:** 39.0% (Long-term, relative to S&P 500)

**Analysis:** The MRI suggests a low-risk environment. However, the RSI indicates that the stock is overbought, potentially signaling a pullback. The PPO being negative and the hybrid signal both suggest caution.

**4. Recent News & Significant Events**

*   **Volatility:** Recent news indicates notable stock volatility due to recent events.
*   **Analyst Focus:** Analysts are discussing recent performance and outlook in the context of industry and economic factors.

**Analysis:** The news suggests that TMDX has been subject to significant attention, developments, and volatility, which should be monitored closely by investors.

**5. Recent Earnings Analysis**

| 날짜       | EPS  | 예상 EPS |
|------------|------|---------|
| 2025-05-08 | 0.7  | 0.29    |
| 2025-02-27 | 0.19 | 0.22    |
| 2024-10-28 | 0.12 | 0.29    |
| 2024-07-31 | 0.35 | 0.21    |
| 2024-04-30 | 0.35 | 0.03256 |

**Analysis:** The company has consistently beaten EPS estimates in recent quarters, indicating positive financial performance.

**6. Financial Information**

| Quarter      | Revenue | Profit Margin |
|--------------|---------|---------------|
| 2025-03-31   | $0.14B  | 61.47%        |
| 2024-12-31   | $0.12B  | 59.21%        |
| 2024-09-30   | $0.11B  | 55.94%        |
| 2024-06-30   | $0.11B  | 60.59%        |
| 2024-03-31   | $0.10B  | 61.91%        |

| Quarter      | Equity  | ROE    |
|--------------|---------|--------|
| 2025-03-31   | $0.27B  | 9.64%  |
| 2024-12-31   | $0.23B  | 3.00%  |
| 2024-09-30   | $0.21B  | 2.01%  |
| 2024-06-30   | $0.19B  | 6.42%  |
| 2024-03-31   | $0.16B  | 7.65%  |

**Analysis:** The company shows consistent revenue growth and strong profit margins. The Return on Equity (ROE) fluctuates but generally indicates good profitability.

**7. 종합 결론**

Transmedics Group Inc. (TMDX) has demonstrated exceptional performance, significantly outperforming the S&P 500. Recent earnings reports have exceeded expectations, reinforcing the company's financial strength. While the stock is currently in an overbought region, indicating a potential short-term pullback, the long-term outlook remains positive, with an expected outperformance against the S&P 500. Investors should closely monitor market volatility and consider strategic approaches such as selling a portion of their holdings in response to the hybrid signal. Overall, TMDX presents a compelling case for sustained growth in the medical technology sector.
